Abstract
Chimeric antigen receptor-natural killer(CAR-NK)cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells.The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy,such as the complexity of the manufacturing process,clinical adverse events,and solid tumor challenges.To date,CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice.However,each source has advantages and disadvantages.Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation.Therefore,this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.
NETL
NSTL
万方数据